Affiliation:
1. From the Department of Psychiatry, the Rebecca and John Moores University of California San Diego Cancer Center, and Department of Family and Preventive Medicine, University of California, San Diego, CA; for the Women's Healthy Eating and Living (WHEL) Study Group
Abstract
Purpose Women with breast cancer are thought to be vulnerable to depression for reasons associated with impact of diagnosis, treatment, and metabolic/endocrine changes. While the literature shows that most of these women do not become clinically depressed, 15% to 30% report elevated depressive symptoms that may be clinically important. The purpose was to identify and determine the relative importance of predictors of depressive symptoms in women treated for early-stage breast cancer. Patients and Methods A total of 2,595 women (≤ 4 years following completion of initial treatment for early-stage breast cancer) provided data on cancer-related variables, personal characteristics, health behaviors, physical functioning/symptoms, and psychosocial variables. Participants were divided into high or low depressive groups using the Center for Epidemiologic Studies Depression Scale screening form. Results Results of the binary logistic regression analysis were significant (overall R2 = 32.4%). Before entry of psychosocial variables, younger age, being unmarried, poorer physical functioning, and more vasomotor and gastrointestinal symptoms were significant risk factors for elevated depressive symptoms (R2 = 16.1%), but objective cancer-related variables were not. After inclusion of psychosocial variables in the model (ΔR2 = 16.3%), none of the preceding variables remained significant. Greater risk for depressive symptoms was associated with stressful life events, less optimism, ambivalence over expressing negative emotions, sleep disturbance, and poorer social functioning. Conclusion Depressive symptoms in women treated for early-stage breast cancer are not associated with objective cancer-related factors. Rather, they are most strongly linked with many subjective psychosocial variables.
Publisher
American Society of Clinical Oncology (ASCO)
Reference59 articles.
1. Tamoxifen and Depression: More Evidence From the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study
2. Quality of Life and Tamoxifen in a Breast Cancer Prevention Trial
3. Somerset W, Stout SC, Miller AH, et al: Breast cancer and depression. Oncology (Huntington) 18:1021,2004-1034,
4. Bardwell WA, Major JM, Dimsdale JE, et al: Predictors of depressive symptoms in breast cancer survivors. Psychosomatics 45:164,2004, (abstr)
5. Depression and degree of acceptance of adjuvant cytotoxic drugs
Cited by
167 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献